Therapeutic monoclonal antibodies: ScFv patents as a marker of a new class of potential biopharmaceuticals

Brazilian Journal of Pharmaceutical Sciences

Volumn 47, Issue 1, 2011, Pages 31-39

  Pucca, Manuela Berto ^a   Bertolini, Thaís Barboza ^a   Barbosa, José Elpidio ^a   Galina, Simone Vasconcelos Ribeiro ^a   Porto, Geciane Silveira ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Monoclonal antibodies; Recombinant antibodies; ScFv. Biopharmaceuticals

Indexed keywords

BISPECIFIC ANTIBODY; BITE M 103; C 65K A; F 5 SCFV PEG; IMMUNOGLOBULIN; IMMUNOLIPOSOME; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; OKT 3; RECOMBINANT ANTIBODY; SGN 17; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; T 8466; UNCLASSIFIED DRUG; VENOM ANTISERUM;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN ANTIBODY REACTION; AUTOIMMUNE DISEASE; BREAST CANCER; CANCER IMMUNOTHERAPY; CHINA; COLORECTAL CANCER; DRUG APPROVAL; DRUG INFORMATION; DRUG LEGISLATION; DRUG RESEARCH; DRUG SAFETY; HEMATOLOGIC MALIGNANCY; HUMAN; HUMORAL IMMUNITY; IMMUNOGENICITY; MELANOMA; NONHUMAN; OVARY CANCER; PATENT; REVIEW; UNITED KINGDOM; UNITED STATES;

EID: 79957563560     PISSN: 19848250     EISSN: 21759790     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. ADAMS, G.P.; SHALLER, C.C.; DADACHOVA, E.; SIMMONS, H.H.; HORAK, E.M.; TESFAYE, A.; KLEIN-SZANTO, A.J.; MARKS, J.D.; BRECHBIEL, M.W.; WEINER, L.M. A single treatment of yttrium-90-labeled CHX-A"-C6.5 diabody inhibits the growth of established human tumor xenografts in immunodeficient mice. Cancer Res., v.64, p.6200-6206, 2004.
2. BALLOW, M. Ximab this and-zumab that! Has the magic bullet arrived in the new millennium of medicine and science? J. Allergy Clin. Immunol., v.116, p.738-743, 2005.
3. CALDAS, C.; COELHO, V.P.; RIGDEN, D.J.; NESCHICH, G.; MORO, A.M.; BRÍGIDO, M.M. Design and synthesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen. Design and synthesis of germline-based hemi-humanized single-chain Fv against the CD18 surface antigen. Protein Eng., v.13, p.353-360, 2000.
4. CHESTER, K.A.; HAWKINS, R.E. Clinical issues in antibody design. Trends Biotechnol., v.13, p.292-300, 1995.
5. DUBEL, S. (Ed.) Handbook of therapeutic antibodies. Local de publicação?: Wiley, Weinhem (verificar o nome da Editora), 2007. v.1-3. Volume I: Technologies, Volume II: Emerging Developments, Volume III: Approved Therapeutics.
6. EBBINGHAUS, C.; RONCA, R.; KASPAR, M.; GRABULOVSKI, D.; BERNDT, A.; KOSMEHL, H.; ZARDI, L.; NERI, D. Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int. J. Cancer, v.116, p.304-313, 2005.
7. FARDELONE, L.C.; BRANCHI, B.A. Avanços recentes do mercado farmacêutico. Rev. FAE, v.9, p.139-152, 2006.
8. FOOD AND DRUG ADMINISTRATION. Therapeutic biologicals products approvals. Available at: Accessed on: 10 jul. 2009.
9. GEORGE A. J.T.; HUSTON, J.S.; HABER E. Exploring and exploiting the antibody and Ig superfamily combining sites. Nat. Biotechnol., v.14, p.584, 1996.
10. GUPTA, P.;, HAN, S.Y.; HOLGADO-MADRUGA, M.; MITRA, S.S.; LI, G.; NITTA, R.T.; WONG, A.J. Development of an EGFRvIII specific recombinant antibody. BMC Biotechnol., v.10, p.1-13, 2010.
11. HEALTH ON NET. HON. Doenças Auto-Imunes. Available at: Accessed on: 15 jul. 2009.
12. INSTITUTO NACIONAL DA PROPRIEDADE INDUSTRIAL. INPI. O que é patente? Available at: Accessed on: 15 dez. 2009.
13. KÖHLER, G.; MILSTEIN, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, v.256, p.495-497, 1975.
14. KOZAK, R.W.; WALDRMAM, T.A.; ATCHER, R.W.; GANSOW, O.A. Radionuclideconjugated monoclonal antibodies: a synthesis of immunology, inorganic chemistry and nuclear science. Trends Biotechnol., v.4, p.259-264, 1985.
15. KÜHLER, G.; MILSTEIN, C. Continuous cultures of focused cells secreting antibody of predefined specificity. Nature, v.256, 495-497, 1975.
16. LASTRES, H. M. M.; FERRAZ, J. C. Economia da Informação, do Conhecimento e do Aprendizado. In: LASTRES, H. M. M.; ALBAGLI, S. (Orgs.) Informação e globalização na era do conhecimento. Rio de Janeiro: Campus, 1999. p.27-29.
17. LONBERG, N. Human antibodies from transgenic animals. Nature Biotech., v.23, p.1117-1125, 2005.
18. LORIMER I.A.; HAFKEMEYER, A.; BEERS R.A.; PEGRAM C.; BIGNER D.D.; PASTAN, I. Recombinant immunotoxins specific for a mutant epidermal growth factor receptor: Targeting with a single chain antibody variable domain isolated by phage display. Proc. Nat. Acad. Sci. USA, v.93, p.14815-14820. 1996.
19. MARANHÃO, A.Q.; BRÍGIDO, M.M. Expression of anti-Z-DNA single chain antibody variable fragment on the filamentous phage surface. Braz. J. Med. Biol. Res., v.33, p.569-579, 2000.
20. MAYNARD, J.; GEORGIOU, G. Antibody engineering. Annu. Rev. Biomed. Eng., v.2, p.339-376, 2000.
21. NELLIS, D.F.; GIARDINA, S.L.; JANINI, G.M.; SHENOY, S.R.; MARKS, J.D.; TSAI, R.; DRUMMOND, D.C.; HONG, K.; PARK, J.W.; OUELLETTE, T.F.; PERKINS, S.C.; KIRPOTIN, D.B. Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol. Prog., v.21, p. 221-232, 2005.
22. NOBELPRIZE. O Prêmio Nobel. Available at: Accessed on: 16 jul. 2009.
23. OLAFSEN, T.; CHEUNG, C.W.; YAZAKI, P.J.; LI, L.; SUNDARESAN, G.; GAMBHIR, S.S.; SHERMAN, M.A.; WILLIAMS, L.E.; SHIVELY, J.E.; RAUBITSCHEK, A.A.; WU, A.M. Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications. Protein Eng. Des. Sel., v.17, p.21-27, 2004.
24. OLIVEIRA, J.G.; SOARES, S.G. SOARES, A. M., GIGLIO, J. R.; TEIXEIRA, J.E.; BARBOSA J.E. Expression of human recombinant antibody fragments capable of partially inhibiting the phospholypase activity of crotalus durissus terrificus Venom. Basic Clin. Pharmacol. Toxicol., v.105, p.84-91, 2000.
25. PIGNATARI, C.G.; TAKESHITA, D.; PARISE, C.B.; SOARES, F.A.; MORAES, J. Z.; HAN, S.W. Carcinoembryonic antigen (CEA) mimicry by an anti-idiotypic scFv isolated from anti-Id 6. C4 hybridoma. J. Biotechnol., v.127, p.615-625, 2007.
26. RADAELLI, V. A nova conformação setorial da indústria farmacêutica mundial: redesenho nas pesquisas e ingresso de novos atores. Rev. Bras. Inov., v.7, p.445-482, 2008.
27. REES, A.R.; STAUNTON, D.; WEBSTER, D.M.; SEARLE, S. J.; HENRY, A. H.; PDERSEN, J. T. Antibody design: beyond the natural limits. Trends Biotechnol., v.12, p.199-206, 1994.
28. REICHERT, J. M.; DEWITZ, M. C. Anti-infective monoclonal antibodies: perils and promise of development. Nature Rev. Drug Discov., v. 5, p. 191-195, 2006.
29. REICHERT, J. M.; ROSENSWEIG, C. J.; FADEN, L. B.; DEWITZ, M. C. Monoclonal antibody successes in the clinic. Nature Biotechol., v. 23, p.1073-1078, 2005.
30. ROQUE, A.C.A.; LOWE, C.R.; TAIPA, M.A. Antibodies and genetically engineered related molecules: production and purification. Biotechnol. Prog., v.20, p.639-654, 2004.
31. ROSEN S. T., WINTER J. N.; EPSTEIN A.L. Application of monoclonal antibodies to tumor diagnosis and therapy. Ann. Clin. Lab. Sci., v.13, p.173-184, 1983.
32. SCHROFF, R.W.; FOON, K.A.; BEATTY, S.M.; OLDHAM, R.K.; MORGAN, A.C. JR. Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy. Cancer Res., v.45, p.879-885, 1985.
33. SHAWLER, D.L.; BARTHOLOMEW, R.M.; SMITH, L.M.; DILLMAN, R.O. Human immune response to multiple injections of murine monoclonal IgG. J. Immunol., v.135, p.1530-1535, 1985.
34. SILVERTON, E.W.; NAVIA, M.A.; DAVIES, D.R. Three-dimensional structure of an intact human immunoglobulin. Proc. Nat. Acad. Sci. USA, v.74, p.5140-5144, 1977.
35. SMITH, G.P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science, v.228, p.1315-1317, 1985.
36. STREBHARDT, K.; ULLRICH, A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nature Rev. Cancer, v. 8, p.473-480, 2008.
37. TAMAROZZI, M.B.; SOARES, S.G.; MARCUSSI, S.; GIGLIO, J.R.; BARBOSA, J.E. Expression of recombinant human antibody fragments capable of inhibiting the phospholipase and myotoxic activities of Bothrops jararacussu venom. Biochim. Biophys. Acta, v.1760, p.1450-1457, 2006.
38. TURNER, D.J.; RITTER, M.A.; GEORGE, A.J.T. Importance of the linker in expression of single chain Fv antibody fragments-optimisation of peptide sequence using phage display technology. J. Immunol. Methods, v.205, p.43-54, 1997.
39. WALDMANN, T. A. Immunotherapy: past, present and future. Nature Med., v.9, p.269-277, 2003.
40. WINTLOW, M.; FILPPULA, D. Single-chain Fv proteins and their fusion proteins. Methods, v.2, p.97-105, 1991.
41. WORLD INTELLECTUAL PROPERTY ORGANIZATION. WIPO. Available at: . Accessed on: 10 set. 2009.